Cargando…
CAR T cells remain during long-term cancer remission
A number of chimeric antigen receptor (CAR) T cell-based therapies are now approved by the FDA for the treatment of cancer. A study published in Nature found that CAR T cells are still present in two patients who remain cancer-free over a decade after they received CAR T cell therapy as part of a cl...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9053192/ https://www.ncbi.nlm.nih.gov/pubmed/35603282 http://dx.doi.org/10.1038/s43856-022-00092-w |